Table 1 Patient baseline demographic data and clinical characteristics
EC-Doc | FEC120 | |
|---|---|---|
Variable | n =689 | n =675 |
Age, years | ||
Median (range) | 54 (27–71) | 54 (25–71) |
Mean (s.d.) | 53.3 (9.95) | 53.9 (9.85) |
Body mass index, kg m −2 | ||
Median (range) | 25.9 (15.6–53.5) | 25.9 (16.9–48.2) |
Mean (s.d.) | 26.8 (5.2) | 26.8 (4.9) |
Menopausal status, n (%) | ||
Premenopausal | 252 (36.6) | 253 (37.5) |
Postmenopausal | 428 (62.1) | 417 (61.8) |
Unknown | 9 (1.3%) | 5 (0.7) |
ECOG performance status, n (%) | ||
0 | 298 (43.3) | 274 (40.6) |
1 | 294 (42.7) | 303 (44.9) |
2 | 45 (6.5) | 49 (7.3) |
3 | 3 (0.4) | 1 (0.1) |
4 | 4 (0.6) | 3 (0.4) |
Unknown | 45 (6.5) | 45 (6.7) |
Histological subtype, n (%) | ||
Ductal | 486 (70.5) | 467 (69.2) |
Lobular | 144 (20.9) | 142 (21.0) |
Mixed ductal-lobular | 53 (7.7) | 60 (8.9) |
Undefined | 6 (0.9) | 6 (0.9) |
Tumour location, n (%) | ||
Left | 340 (49.3) | 343 (50.8) |
Right | 344 (49.9) | 331 (49.0) |
Unknown | 5 (0.7) | 1 (0.1) |
Tumour size, n (%) | ||
T1 | 189 (27.4) | 199 (29.5) |
T2 | 393 (57.0) | 355 (52.6) |
T3 | 84 (12.2) | 81 (12.0) |
T4 | 22 (3.2) | 38 (5.6) |
Unknown | 1 (0.1) | 2 (0.3) |
Number of positive axillary lymph nodes, n (%) | ||
1–3 (pN1) | 1 (0.1) | 3 (0.4) |
4–9 (pN2) | 417 (60.5) | 405 (60.0) |
⩾10 (pN3) | 270 (39.2) | 265 (39.3) |
Unknown | 1 (0.1) | 2 (0.3) |
Histological grade, n (%) | ||
Grade 1+2 | 346 (50.2) | 340 (50.4) |
Grade 3 | 300 (43.5) | 274 (40.6) |
Unknown | 43 (6.2) | 61 (9.0) |
Hormone receptor status, n (%) | ||
Negative | 170 (24.7) | 162 (24.0) |
Positive | 519 (75.3) | 513 (76.0) |
HER2 status, n (%) | ||
Negative | 476 (69.1) | 473 (70.1) |
Positive | 149 (21.6) | 153 (22.7) |
Undefined | 64 (9.3) | 49 (7.3) |
Additional treatment, n (%) | ||
Radiotherapy after chemotherapy | 591 (85.8) | 570 (84.4) |
Radiotherapy between chemotherapy courses | 98 (14.2) | 105 (15.6) |
Endocrine treatment | 84 (12.2) | 73 (10.8) |
